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Attenuation of Leptin Action
and Regulation of Obesity
by Protein Tyrosine Phosphatase 1B
associated with high circulating levels of leptin, sug-
gesting that resistance to leptin action may underlie
most types of obesity (Maffei et al., 1995). Studies with
mice indicate that leptin resistance may arise through
a defect in transport across the blood-brain barrier, and/
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Much of how leptin signaling is regulated in vivo re-3 The Arthur and Sonia Labatt Brain Tumour
Research Centre mains to be discovered. The receptor for leptin (OBR)
belongs to the class of type I cytokine receptors thatThe Hospital for Sick Children
Toronto, Ontario M5G 1X8 utilize an associated Janus kinase (Jak) to transmit sig-
nals to downstream molecules (Tartaglia, 1997). Binding4 Department of Biochemistry and Molecular
Biology of leptin activates Jak2, which in turn phosphorylates
the receptor and the signal transducers and activatorsMerck Frosst Center for Therapeutic Research
Pointe Claire-Dorval, Quebec H9R 4P8 of transcription 3 (Stat3) protein. Tyrosine phosphoryla-
tion of Stat3 on Y705 allows it to homodimerize, andCanada
leads to its subsequent translocation to the nucleus
where it can mediate transcription of target genes. One
such gene is the suppressors of cytokine signaling 3Summary
(Socs-3) protein, which can function in a negative feed-
back loop to inhibit leptin signaling (Bjorbaek et al.,Common obesity is primarily characterized by resis-
1998, 1999, 2000). However, other negative regulatorytance to the actions of the hormone leptin. Mice defi-
components of leptin signaling remain unknown.cient in protein tyrosine phosphatase 1B (PTP1B) are
We and others previously demonstrated that miceresistant to diabetes and diet-induced obesity,
lacking the protein tyrosine phosphatase 1B (PTP1B)prompting us to further define the relationship be-
exhibit increased sensitivity to insulin and resistance totween PTP1B and leptin in modulating obesity. Leptin-
high-fat diet-induced diabetes and obesity (Elchebly etdeficient (Lepob/ob) mice lacking PTP1B exhibit an atten-
al., 1999; Klaman et al., 2000). Interestingly, althoughuated weight gain, a decrease in adipose tissue, and
serum leptin in these mice are lower compared to wild-an increase in resting metabolic rate. Furthermore,
type controls, they do not exhibit hyperphagia. Collec-PTP1B-deficient mice show an enhanced response
tively, this raised the possibility that PTP1B might nega-toward leptin-mediated weight loss and suppression
tively regulate the actions of leptin in maintaining bodyof feeding. Hypothalami from these mice also display
weight.markedly increased leptin-induced Stat3 phosphory-
In this study, we provide genetic evidence that PTP1Blation. Finally, substrate-trapping experiments dem-
regulates body weight via leptin-independent andonstrate that leptin-activated Jak2, but not Stat3 or
-dependent pathways. In the complete absence of lep-the leptin receptor, is a substrate of PTP1B. These
tin, loss of PTP1B is able to attenuate weight gain with-results suggest that PTP1B negatively regulates leptin
out a discernible change in food intake. However, ad-signaling, and provide one mechanism by which it may
ministration of exogenous leptin also reveals that PTP1Bregulate obesity.
deficiency leads to enhanced leptin sensitivity. Further-
more, we demonstrate that Jak2 is a substrate of PTP1B
Introduction within the leptin signaling pathway. Together, these re-
sults propose how PTP1B may regulate obesity, and
Obesity (Spiegelman and Flier, 2001) is a widespread identifies it as an attractive therapeutic target for treating
disorder reaching epidemic proportions in industrialized the disorder.
societies. It is well established that the peptide hormone
leptin plays a central role in feeding and adiposity (Ahima Results and Discussion
and Flier, 2000; Friedman and Halaas, 1998). Its primary
site of action occurs in the hypothalamus, where it sig- Leptin-Independent Effects of PTP1B on Obesity
nals to inhibit feeding (Fei et al., 1997). Indeed, loss-of- To explore the possibility that PTP1B modulates leptin
function mutations in leptin (Zhang et al., 1994) or its action in regulating body weight, we introduced the
receptor (Chen et al., 1996) in mice result in severe hy- PTP1B null mutation into the leptin-deficient mouse
perphagia leading to morbid obesity. Despite leptin’s (Lepob/ob) model. Lepob/ob mice are sterile, and thus, to
integral role in body weight regulation, its use in treating generate mice deficient in both leptin and PTP1B, we
human obesity has been relatively unsuccessful (Heyms- first bred Lep/ob mice (containing one wild-type leptin
field et al., 1999). Most cases of human obesity are allele) and PTP1B (/, /, or /) mice (Elchebly et al.,
1999). Identification of the mutant PTP1B allele was per-
formed by Southern blot analysis and the ob mutation5 Correspondence: michel.tremblay@mcgill.ca
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Figure 1. Decreased Obesity in Lepob/ob Mice Lacking PTP1B
Lean mice (with at least one Lep allele) were used as controls. Error bars represent standard error of the mean.
(A) Weight gain of male mice (n  23–25).
(B) Weight gain of female mice (n  15–32).
(C) Physical appearance of 7-month-old male Lepob/ob and double-mutant mice.
(D) Decreased weight of subcutaneous fat pads in double-mutant mice (n  8–9).
by genomic PCR (data not shown). By 4 weeks of age, growth retardation. To confirm this hypothesis, we ana-
lyzed the amount of fat in the mice. Indeed, significantall Lepob/ob mice were physically distinguishable to be
obese, compared to lean controls (containing at least differences in the weights of the subcutaneous fat pads
were evident between double-mutant and Lepob/ob miceone wild-type Lep allele). However, significant differ-
ences in body weight between double-mutant (PTP1B/ (Figure 1D), even when expressed as a percentage of
total body weight (data not shown).Lepob/ob) and Lepob/ob mice became evident by 7–8 weeks
for males (p  0.01), and by 4–5 weeks for females (p  Despite the absence of leptin, it is conceivable that
the loss of PTP1B in Lepob/ob mice may affect feeding0.05) (Figures 1A and 1B). By 12 weeks of age, double-
mutant male mice weighed 12% less than Lepob/ob males behavior, and thus body weight. To verify this possibility,
food intake over a 5 day period was monitored. However,(p  0.01), and double-mutant females weighed 12%
less than Lepob/ob females (p  0.05). Interestingly, food intake in Lepob/ob mice was unaffected by their
PTP1B genotype (Figure 2A). Similarly, resting metabolicthroughout the study, Lepob/ob mice heterozygous for
PTP1B displayed an intermediate weight gain between rate (RMR) was unaltered, as determined by oxygen
consumption on a per mouse basis (Figure 2B). How-Lepob/ob mice and double-mutant mice, suggesting that
inhibiting half the levels of PTP1B may be sufficient to ever, when normalized to body weight, RMR was signifi-
cantly increased by 29% (p  0.044) in double mutantsinvoke some weight loss.
Although double-mutant mice weighed significantly compared to Lepob/ob controls (data not shown), similarly
to previously reported results (Klaman et al., 2000). Nev-less than Lepob/ob mice, their average length was not
significantly different (Figure 1C and data not shown), ertheless, these results suggest that PTP1B can regulate
obesity in a leptin-independent manner.suggesting a difference in body composition rather than
Enhanced Leptin Action in PTP1B-Deficient Mice
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Figure 2. Metabolic Parameters and Glucose Homeostasis in Lepob/ob and Double-Mutant Mice
Error bars represent standard error of the mean.
(A) Five day food intake for male mice at ages 7–8 weeks (n  11–15) and 12–13 weeks (n  7–13).
(B) Resting metabolic rate of male mice (n  5–7).
(C) Glucose tolerance tests (n  7–9).
(D) Fasting blood glucose levels (n  10–12).
Since the Lepob/ob obesity model is also used to study induced weight loss in the mice (Figures 3A and 3B). At
insulin resistance and hyperglycemia, we investigated a leptin dose of 2.0 mg/kg, there was no significant
whether genetic ablation of PTP1B in these mice could difference in weight loss between double-mutant and
alleviate the associated diabetic symptoms. We moni- Lepob/ob mice. When the dose was reduced to 0.5 mg/
tored glucose homeostasis in the mice by glucose toler- kg, double-mutant mice tended to lose slightly more
ance tests (GTTs) and fasting glucose levels. Following weight (day 4: Lepob/ob, 4.86  0.33 g versus double-
an intraperitoneal (i.p.) glucose injection, double-mutant mutant, 6.26  0.49 g; p  0.050). Importantly, during
mice displayed an enhanced ability to maintain lower these experiments, double-mutant mice displayed in-
glucose levels when compared to Lepob/ob mice (Figure creased sensitivity to leptin-mediated feeding inhibition
2C). In addition, double-mutant mice also displayed at the lower dose (Figure 3D). These results suggest
lower (p  0.040) fasting blood glucose levels (Figure that loss of PTP1B may sensitize Lepob/ob mice toward
2D). These results demonstrate that loss of PTP1B allevi- low doses of leptin.
ates the diabetes associated with this severe obesity Since the Lepob/ob mouse is highly sensitive toward
model, even in the absence of leptin. leptin, it is possible that the effects of PTP1B deficiency
on obesity in this model may be underestimated. Thus,
we wanted to further extend our findings to lean micePTP1B Negatively Regulates Leptin Action
(wild-type for leptin) which are more resistant to leptin.However, to investigate whether PTP1B plays a direct
In addition, we further reduced the leptin dose to 0.1role in leptin action and signaling, we peripherally admin-
mg/kg. For mice that are wild-type for PTP1B, leptinistered leptin into double-mutant and Lepob/ob mice, and
induced weight loss by day 1, but the effects rapidlymonitored both weight change and food intake. Mice
leveled off (Figure 3C). In fact, some mice even beganwere first mock treated with PBS to accustom them to
to regain some weight (data not shown). In contrast,the experimental procedure. Subsequently, mice were
PTP1B knockout mice lost weight in response to leptininjected i.p. twice daily with leptin doses of either 2
mg/kg or 0.5 mg/kg body weight. At both doses, leptin for the duration of the study, suggesting that loss of
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Figure 3. Increased Leptin Sensitivity in Mice Lacking PTP1B
Error bars represent standard error of the mean.
(A and B) Weight loss of Lepob/ob (diamonds) or double-mutant (triangles) mice in response to the indicated doses of leptin (n  3–5).
(C) Weight loss of PTP1B wild-type (diamonds) or knockout (triangles) lean mice in response to 0.1 mg/kg leptin (n  7–8).
(D) Increased sensitivity toward leptin-mediated food inhibition in mice lacking PTP1B (n  3–8). Baseline consumption was measured during
PBS injections. Dark bars represent wild-type mice, and light bars represent knockout mice.
PTP1B results in increased leptin sensitivity. Consistent dose, Lepob/ob mice displayed minimal leptin-mediated
Stat3 phosphorylation (Figure 4B). Indeed, previous ex-with this notion, in response to leptin, PTP1B knockout
mice also decreased their feeding, whereas wild-type periments have shown that a certain threshold of leptin
is required for Stat3 activation in the hypothalamus (El-mice did not (Figure 3D). It is worthwhile to note that
the enhanced leptin sensitivity seen in these PTP1B Haschimi et al., 2000). Importantly, though, double-
mutant mice exhibited a more robust activation of Stat3deficient mice is comparable to that reported for neuro-
peptide Y knockout mice (Erickson et al., 1996). compared to Lepob/ob mice (Figure 4B). These results
suggest that loss of PTP1B in Lepob/ob mice results inPrevious studies have shown that leptin activates
Stat3 in the hypothalamus of mice (Vaisse et al., 1996). an increase in sensitivity to leptin-mediated signaling
toward Stat3.Thus, we sought to extend our findings to the molecular
level, and to assess whether PTP1B plays a direct role
in hypothalamic leptin signaling. Our initial investigation Leptin-Activated Jak2 Is a Substrate of PTP1B
Overexpression studies in cells have shown that leptin-revealed that PTP1B protein could be detected by im-
munoblotting from microdissected hypothalami (Figure mediated Stat3 activation occurs via the tyrosine kinase
Jak2 (Bjorbaek et al., 1997). In addition, molecular mod-4A). Equal loading was confirmed by immunoblotting
against Erk, which is of similar size and ubiquitously eling studies predict Jak2 as a candidate substrate for
PTP1B (Salmeen et al., 2000). However, we could notexpressed. We then looked at leptin-induced Stat3
phosphorylation using phospho-specific antibodies to- detect Jak2 phosphorylation in the hypothalamus by
immunoprecipitation with Jak2 or phospho-specific an-ward Y705 of Stat3. For these studies, we peripherally
administered leptin at a dose of 0.5 mg/kg, since this tibodies, similar to what has previously been reported
in rats (McCowen et al., 1998). It is likely that a verywas shown to differentially inhibit food intake between
Lepob/ob and double-mutant mice (Figure 3C). At this small subset of Jak2 molecules is activated upon leptin
Enhanced Leptin Action in PTP1B-Deficient Mice
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Figure 4. PTP1B Is a Negative Regulator of Leptin-Mediated Stat3 Activation
(A) Expression of PTP1B in the hypothalamus. Tissue was homogenized in RIPA lysis buffer and immunoblotted with PTP1B and Erk antibodies.
Lysates from mouse embryonic fibroblasts immortalized with the SV40 large T antigen (Cheng et al., 2001) were used as a control.
(B) Increased leptin-mediated hypothalamic Stat3 activation in double-mutant mice. Enriched nuclear lysates from the hypothalamus were
immunoblotted with antibodies against phospho-Stat3 and Stat3 antibodies. Each lane represents one mouse.
(C) Jak2 but not Stat3 or OBRb is a substrate of PTP1B. 293LA cells (lane 1) were transfected with the long form of the leptin receptor (lanes
2–7) and either GST alone (lane 2), GST-PTP1B WT (lanes 3 and 4), or GST-PTP1B D181A (lanes 5 and 6). After serum starvation, cells were
either left untreated (lanes 3 and 5) or stimulated with 100 nM leptin (lanes 1, 2, 4, 6, and 7). Cell lysates were subjected to pull-downs with
glutathione beads and then analyzed by immunoblotting with the indicated antibodies.
treatment. Therefore, we resorted to a heterologous sys- structurally diverse (Tonks and Neel, 2001). Within this
family, the transmembrane PTP, CD45, and TC-PTPtem to investigate whether Jak2 could be a substrate
of PTP1B. We employed a D181A mutant of PTP1B that have also recently been demonstrated to dephosphory-
late multiple Jak family members (Irie-Sasaki et al., 2001;was previously shown to possess diminished catalytic
activity but retained binding ability, thus producing a Simoncic et al., 2002). It is interesting to note that Jak2,
which is known to associate with cytokine receptors“substrate-trapping mutant” (Flint et al., 1997).
We coexpressed GST alone or GST-tagged PTP1B at the plasma membrane, has also been found to be
detected at the endoplasmic reticulum (Lavoie et al.,(WT or D181A) with the long form of the leptin receptor
(OBRb) into 293LA cells (Jak2-expressing) and asked 2000), where PTP1B localization and action predomi-
nate (Frangioni et al., 1992; Haj et al., 2002). Thus anwhether we could detect Jak2 in a complex with PTP1B.
To do so, pull-downs of lysates were performed with intriguing question is whether CD45, TC-PTP, PTP1B,
and other PTPs may coordinately regulate aspects ofglutathione beads. From Figure 4C (left panels), it is
clear that neither beads alone, GST, nor GST-PTP1B Jak-mediated signaling, both spatially as well as tempo-
rally.(WT) could precipitate Jak2. In contrast, GST-PTP1B
(D181A) was found to precipitate Jak2, but only in leptin-
treated cells (lane 6). Moreover, probing of the same pull-
downs with the appropriate antibodies failed to detect Perspectives
Recent studies have shown that in vivo administration ofeither Stat3 or the leptin receptor, suggesting that Jak2
is the specific target for PTP1B in this pathway. Finally, leptin can induce signaling in peripheral insulin-sensitive
tissues, and that synergistic activation with insulin mayas controls, we immunoblotted the total cell lysates
(TLC) to ensure that similar amounts of the appropriate also occur (Kim et al., 2000). Moreover, the brain-specific
knockout of the insulin receptor in mice has elegantlyproteins were transfected in each case (Figure 4C, right
panels). demonstrated insulin’s role in the central regulation of
body weight (Bruning et al., 2000). Since PTP1B-defi-Thus, these results demonstrate that Jak2 is a poten-
tial substrate of PTP1B and, taken together, suggest cient mice display enhanced insulin signaling and action
(Elchebly et al., 1999; Klaman et al., 2000), one mightthat PTP1B negatively regulates leptin signaling via de-
phosphorylation of Jak2. Consistent with this notion, speculate whether PTP1B coordinately regulates both
insulin and leptin signaling, peripherally and/or centrally,PTP1B has also been suggested to antagonize inter-
feron (type II cytokine) signaling via TYK2 and Jak2 (My- to maintain the homeostatic control of body weight.
Leptin is widely accepted as a critical regulator ofers et al., 2001). Thus, it will be interesting to determine
whether PTP1B regulates Jak2 signaling in other path- energy metabolism. However, an increasing amount of
evidence suggests that it may also play an essential roleways or cell types.
PTP1B belongs to the large family of protein tyrosine to prevent lipid overaccumulation in nonadipose tissues
(“lipotoxicity”; Unger, 2002). It is thought that the excessphosphatases (PTPs) that are both functionally and
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Glucose Studiesof fatty acids within the cell can attenuate insulin signal-
Male mice (n 7–12) were used as they are more hormonally stable.ing, ultimately leading to insulin resistance (Shulman,
For glucose measurements, age-matched mice (13–14 weeks old)2000). If PTP1B does indeed play a role in peripheral
were fasted overnight (16–18 hr) and blood withdrawn from the tail
leptin signaling, this may contribute in part to both the was analyzed using a strip test Vitros 250 analyzer. For glucose
diabetes and obesity resistance phenotypes of the tolerance tests, fasted mice were intraperitoneally administered glu-
cose (1 mg per g body weight) and blood was withdrawn from theknockout mice. Additional studies with tissue-specific
tail at t  0, 30, 60, and 120 min.knockouts of PTP1B should help address these ques-
tions, and is currently underway.
Leptin StudiesIn summary, our results, in conjunction with those of
For leptin studies, mice (n  3–5) were individually caged. During
Zabolotny et al. in this issue of Developmental Cell, the first 3 or 4 days, mice were injected (i.p.) twice daily (12:00 pm
provide compelling evidence for PTP1B in the regulation and 6:00 pm EST) with PBS to establish a baseline of weight change
of obesity through leptin-dependent and -independent and food intake. Afterward, PBS was replaced with murine leptin at
the indicated dose. In the ob/ob background, age-matched malepathways. Importantly, loss of PTP1B in Lepob/ob mice
mice between 8 and 10 weeks were used. For the lean mice studies,increases their sensitivity toward leptin-mediated hypo-
age-matched female mice (backcrossed into the Balb/c backgroundthalamic action (feeding inhibition) as well as signaling
for three generations) were used.
(Stat3 phosphorylation). In view of the current inade-
quacy of leptin administration (alone) as a means of Hypothalamic Stat3 Activation
combating obesity, our data suggest that pharmacologi- Lepob/ob or double-mutant mice were starved overnight and then
injected (i.p.) with PBS or 0.5 mg/kg leptin, and sacrificed 30 mincal inhibitors of PTP1B hold promise as an alternative
later. The hypothalamus was carefully dissected and lysed using aor a supplement to leptin in the treatment of obesity
Teflon tip homogenizer in 500 l of buffer A (10 mM HEPES [pHdue to leptin resistance.
7.4], 10 mM KCl, 1 mM MgCl2, 1 mM DTT) supplemented with 1
mM sodium orthovanadate, 1 mM PMSF, and Complete EDTA-free
protease inhibitor cocktail (Roche). Lysates were centrifuged atExperimental Procedures
2000  g for 10 min at 4C. The supernatant was transferred to
another tube while the pellet was washed once with buffer A. TheMaterials
pellet was then resuspended in 200 l of buffer B (20 mM HEPESRabbit polyclonal antibodies against PTP1B (Elchebly et al., 1999)
[pH 7.4], 420 mM NaCl, 10 mM KCl, 20% glycerol, 1 mM DTT)and the OBR (Bjorbaek et al., 1997) have been previously described.
supplemented with the above protease and phosphatase inhibitors.Anti-Erk and anti-Stat3 antibodies (pan and phospho) were pur-
The solution was rotated end-over-end for 30 min and then centri-chased from Cell Signal. Anti-Jak2 antibodies were obtained from
fuged at 16000  g at 4C. The supernatant was transferred toUpstate Biotechnology. Murine recombinant leptin was a kind gift
another eppendorf tube (enriched nuclear fraction).from Dr. A.F. Parlow as part of the National Hormone and Peptide
Program of the National Institute of Diabetes and Digestive and
Substrate-Trapping StudiesKidney Diseases.
Details of the PTP1B constructs are described elsewhere (Simoncic
et al., 2002). The plasmid encoding the long form of the murine
Mice leptin receptor (OBRb) was kindly provided by Drs. C. Bjorbaek and
The ob mutation originated from /ob mice (C57BL/6 background) J.S. Flier (Bjorbaek et al., 1997). 293LA cells were transfected by
obtained from Jackson Laboratories. PTP1B mutant mice are a Lipofectamine (Life Technologies) according to the manufacturer’s
hybrid of 129S/v and Balb/c backgrounds. To eliminate effects due instructions. Twenty-four hr posttransfection, cells were starved
to genetic background, we used multiple breeding pairs to generate overnight, and then treated with 100 nM leptin or left unstimulated.
Lepob/ob mice that are wild-type, heterozygous, or homozygous null Forty-eight hr posttransfection, cells were lysed in buffer containing
for PTP1B. For the leptin studies (below), PTP1B wild-type and 50 mM HEPES [pH 7.5], 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA,
knockout lean mice were backcrossed into a Balb/c background 1% Triton X-100, and 10% glycerol (supplemented with Complete
for three generations to minimize genetic background effects. EDTA-free protease inhibitors). Crude lysates were then cleared by
centrifugation at 14000 g. GST-tagged proteins were precipitated
using 25 l of glutathione Sepharose beads (Pharmacia), washed
Genomic PCR for Leptin Alleles extensively in lysis buffer, and then resuspended in SDS sample
Technical advice was generously provided by Sarah M. Wiesbrock buffer. Aliquots were resolved by SDS-PAGE and analyzed by immu-
and Gokhan S. Hotmisligil (Harvard School of Public Health). PCR noblotting with the indicated antibodies.
primers used were 5	-GTC CAA GAT GGA CCA GAC-3	 (forward) and
5	-AGG CAG GGA GCA GCT CTT-3	 (reverse). PCR was performed in Acknowledgments
a buffer (MBI) containing 2 mM MgSO4, 100 pmol of each primer,
0.2 mM dNTPs, and 1 unit of Taq DNA polymerase (MBI). Reaction We would like to thank Drs. A.F. Parlow for murine leptin, James N.
conditions were as follows: denaturation at 94C for 1 min, annealing Ihle and Dwayne L. Barber for Jak constructs, Suhad Ali for 293LA
at 56C for 1 min, and extension at 72C for 1 min for 30 cycles. cells, and Jeffrey S. Flier for leptin receptor antibodies and con-
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